Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World

被引：0
|
作者：
Chen, C. [1 ]
机构：
[1] Zunyi Med Univ, Affiliated Hosp, Zunyi, Guizhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer; Neoadjuvant therapy; PD-1; inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-24
引用
收藏
页码：S579 / S580
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer
    Zhang, Peng
    Dai, Jie
    Sun, Fenghuan
    Xia, Haoran
    He, WenXin
    Duan, Liang
    Liu, Ming
    Zhao, Deping
    Zhu, Yuming
    Jiang, Gening
    ANNALS OF THORACIC SURGERY, 2022, 114 (03): : 949 - 958
  • [22] Real-world comparison of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer: a retrospective cohort study of treatment outcomes
    Hu, Yan
    Ren, Siying
    Feng, Juan
    Zeng, Chao
    Yang, Lulu
    Liu, Jinyou
    Wu, Fang
    Liu, Wenliang
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02)
  • [23] Neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Xie, Hui
    Shi, Xuejun
    Wang, Guangshun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (06): : 2521 - 2536
  • [24] Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Lochrin, Sarah E.
    Forde, Patrick M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (08) : 415 - 423
  • [25] Neoadjuvant therapy for resectable non-small cell lung cancer
    Welcker, Katrin
    Jonigk, Danny
    Kropf-Sanchen, Cornelia
    Tufman, Amanda
    Draube, Andreas
    Stenzinger, Albrecht
    Zaatar, Mohamed
    Thomas, Michael
    PNEUMOLOGIE, 2025, 79 (01): : 16 - 24
  • [26] Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
    Travert, Camille
    Tomasini, Pascale
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 401 - 405
  • [27] EFFICACY OF SALVAGE CHEMOTHERAPY AFTER IMMUNE CHECKPOINT INHIBITOR IN NON-SMALL CELL LUNG CANCER PATIENTS
    Okamatsu, Yuki
    Inoue, Shigesato
    Utsumi, Takahiro
    Kayukawa, Takafumi
    Uryu, Kazuyasu
    Inoue, Katsuhiro
    Tsubouchi, Kazuya
    Harada, Taishi
    RESPIROLOGY, 2018, 23 : 286 - 286
  • [28] Neoadjuvant Combination Sintilimab plus Chemotherapy in Patients with Resectable Stage IIIA Non-Small Cell Lung Cancer.
    Ma, K.
    Sun, C.
    Jia, X.
    Wang, X.
    Xu, Y.
    Guo, Y.
    Qiu, S.
    Shao, G.
    Zhang, P.
    Liu, Y.
    Ma, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S650
  • [29] 3-year update of neoadjuvant atezolizumab plus chemotherapy in patients with resectable non-small cell lung cancer
    Henick, Brian S.
    Gainor, Justin F.
    Awad, Mark M.
    Chiuzan, Codruta
    Izard, Stephanie
    Georgis, Yohanna
    Koch, Peter D.
    Garofano, Robert F.
    Wong, Cheryl V.
    Saqi, Anjali
    Grindheim, Jessica M.
    Schulze, Katja
    Rizvi, Naiyer A.
    Izar, Benjamin
    Taylor, Alison M.
    Shu, Catherine A.
    CANCER RESEARCH, 2023, 83 (08)
  • [30] A Meta-Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer
    Sun, Xinru
    Kang, Tianhua
    Liu, Baodong
    Zhang, Yin
    Huang, Guangming
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (10):
12345